ShanX Medtech BV

ShanX Medtech BV, based in the Netherlands, specializes in developing rapid diagnostic solutions for antimicrobial susceptibility testing, enhancing the efficiency of infection management in healthcare settings. ShanX Medtech BV, founded in 2019 by CEO Sophia Shanko and headquartered in Eindhoven, Netherlands, focuses on the development of advanced diagnostic technologies. In December 2025, ShanX Medtech BV raised EUR 15 million in seed funding co-led by new investors StartGreen Capital, NextGen Ventures, BOM Brabant Ventures, CbusineZ and Invest-NL. The round was part of a larger EUR 23.

85 million seed and grant funding. ShanX Medtech specializes in the development of ultra-rapid Antimicrobial Susceptibility Testing (AST) diagnostics, significantly reducing the turnaround time for reliable test results. Their diagnostic platform accelerates bacterial infection identification, enabling healthcare providers to prescribe effective antibiotic treatments within one hour, compared to traditional methods that take two to seven days. The company primarily serves hospitals, laboratories, and healthcare providers in European markets, focusing on improving patient care through timely and accurate medical decisions.

ShanX Medtech's revenue model is based on direct sales of its diagnostic services to healthcare institutions such as hospitals and specialized laboratories. Revenue is generated through service agreements, where clients pay for each test performed or through subscription models for continuous access to their AST diagnostic solutions. Their flagship product, the rapid AST solution, facilitates efficient treatment decisions in acute care settings, with pricing structures determined through client negotiations and varying based on test volume and contracts. ShanX Medtech plans to use the EUR 23.

85 mn raised in Seed funding to further develop its antibiotic diagnostic system. The company aims to enhance its product offerings and may target additional European markets for expansion by the end of 2026.